[1] Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes.N Engl J Med 2017; 376: 1407–18.
[2] S.J. Haffner, H. Cassells, Hyperglycemia as a cardiovascular risk factor, Am. J. Me. 1013115 (Suppl. 8A) (2003) 6S–11S.
[3] Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373: 2247–57.
[4] Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377: 1228–39.
[5] Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocrine Rev 2012; 33:187–215.
[6] A.J. Motta, J. Koska, P. Reaven, R.Q. Migrino, Vascular protective effects of diabetes
medications that mimic or increase glucagon-like peptide-1 activity, Recent Pat. Cardiovasc. Drug Discov. 7 (2012) 2–9.
[7] Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375:311–22.
[8] Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;(19):1834–44.
[9] Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-130.
[10] Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018 Oct 27;392(10157):1519-1529.
[11] M. Monami, I. Dicembrini, C. Nardini, I. Fiordelli, E. Mannucci, Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials, Diabetes Obes. Metab. 16 (2014) 38–47.
[12] Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Ohman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR EXSCEL Study Group. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018; 6:105–113.
[13] D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med. 6 (2009), e1000097.
[14] Higgins, J. P. et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011).
[15] Guyatt, G. H. et al. Incorporating considerations of resources use into grading recommendations. BMJ 336, 1170–1173, https://doi.org/10.1136/bmj.39504.506319.80 (2008).
[16] Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Making 2005;25(6):646–54.
[17] DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials 2015;45(Pt A):139–45.
[18] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557–60.
[19] Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629–34 [PubMed].
[20] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088–101 [PubMed].
[21] A.K. Bose, M.M. Mocanu, R.D. Carr, C.L. Brand, D.M. Yellon, Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury, Diabetes 54 (2005) 146–151.
[22] T. Zhao, P. Parikh, S. Bhashyam, et al., Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts, J. Pharmacol. Exp. Ther. 317 (2006) 1106–1113.
[23] F. Sun, K. Yu, S. Wu, et al., Cardiovascular safety and glycemic control of glucagon- like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis, Diabetes Res. Clin. Pract. 98 (2012) 386–395.
[24] M. Monami, F. Cremasco, C. Lamanna, et al., Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials,Exp. Diabetes Res. 2011 (2011) 215764.
[25] R.Ratner,J.Han,D.Nicewarner,I.Yushmanova,B.J.Hoogwerf,L.Shen,Cardiovascu- lar safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes, Cardiovasc. Diabetol. 10 (2011) 22.
[26] S.P. Marso, J.B. Lindsey, J.M. Stolker, et al., Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2:3 liraglutide clinical development studies, Diab. Vasc. Dis. Res. 8 (2011) 237–240.
[27] S.E. Inzucchi, D.K. McGuire, New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond, Circulation 117 (2008) 574–584.
[28] Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136: 849–870.
[29] Alvarez-Villalobos NA, Trevino-Alvarez AM, Gonzalez-Gonzalez JG. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375:1797–1798.
[30] Kang YM, Jung CH. Cardiovascular effects of glucagon-like peptide-1 receptor agonists. Endocrinol Metab (Seoul) 2016; 31:258–274.